MA51232A - Indane-amines utiles en tant qu'antagonistes de pd-l1 - Google Patents

Indane-amines utiles en tant qu'antagonistes de pd-l1

Info

Publication number
MA51232A
MA51232A MA051232A MA51232A MA51232A MA 51232 A MA51232 A MA 51232A MA 051232 A MA051232 A MA 051232A MA 51232 A MA51232 A MA 51232A MA 51232 A MA51232 A MA 51232A
Authority
MA
Morocco
Prior art keywords
indane
antagonists
amines useful
amines
useful
Prior art date
Application number
MA051232A
Other languages
English (en)
Inventor
Christopher Lange
Sreenivas Punna
Rajinder Singh
Ju Yang
Penglie Zhang
Original Assignee
Chemocentryx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemocentryx Inc filed Critical Chemocentryx Inc
Publication of MA51232A publication Critical patent/MA51232A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/22Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated the carbon skeleton being further substituted by oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MA051232A 2018-02-22 2019-02-21 Indane-amines utiles en tant qu'antagonistes de pd-l1 MA51232A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862633973P 2018-02-22 2018-02-22

Publications (1)

Publication Number Publication Date
MA51232A true MA51232A (fr) 2020-10-07

Family

ID=67687901

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051232A MA51232A (fr) 2018-02-22 2019-02-21 Indane-amines utiles en tant qu'antagonistes de pd-l1

Country Status (5)

Country Link
US (3) US10568874B2 (fr)
EP (1) EP3755311B1 (fr)
JP (1) JP7387616B2 (fr)
MA (1) MA51232A (fr)
WO (1) WO2019165043A2 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018005374A1 (fr) 2016-06-27 2018-01-04 Chemocentryx, Inc. Composés immunomodulateurs
CA3070794A1 (fr) 2017-07-28 2019-01-31 Chemocentryx, Inc. Composes immunomodulateurs
JP7198269B2 (ja) 2017-08-08 2022-12-28 ケモセントリックス,インコーポレイティド 大員環免疫調節剤
WO2019160882A1 (fr) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Inhibiteurs pd -1/pd-l1
MA51232A (fr) * 2018-02-22 2020-10-07 Chemocentryx Inc Indane-amines utiles en tant qu'antagonistes de pd-l1
WO2019191624A1 (fr) 2018-03-29 2019-10-03 Arbutus Biopharma, Inc. Composés 1,1'-biphényle substitués, analogues de ceux-ci, et procédés les utilisant
WO2019204609A1 (fr) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Inhibiteurs pd-1/pd-l1
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
CN112955435B (zh) 2018-10-24 2024-09-06 吉利德科学公司 Pd-1/pd-l1抑制剂
CA3139526A1 (fr) 2019-05-15 2020-11-19 Chemocentryx, Inc. Composes triaryles pour le traitement de maladies pd-l1
WO2021007386A1 (fr) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes en tant qu'inhibiteurs de pd-l1
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
CN116472045B (zh) * 2020-06-23 2025-05-13 坎莫森特里克斯公司 使用杂芳基联苯基酰胺衍生物治疗癌症的方法

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US5604294A (en) 1991-09-05 1997-02-18 Luly; Jay R. Macrocyclic immunomodulators
IL120266A (en) * 1996-02-28 2005-05-17 Pfizer Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9604926D0 (en) 1996-03-08 1996-05-08 Sandoz Ltd Organic compounds
EP1726580A4 (fr) * 2004-03-15 2008-02-13 Takeda Pharmaceutical Derive de l'acide aminophnylpropano
WO2007126957A2 (fr) 2006-03-31 2007-11-08 Novartis Ag Nouveaux composés
DE102006017175A1 (de) 2006-04-12 2007-10-18 Robert Bosch Gmbh Balancierter Serienmischer für Hochfrequenzsignale
WO2008008059A1 (fr) 2006-07-12 2008-01-17 Locus Pharmaceuticals, Inc. Agents anti-cancer et leurs utilisations
US20080194557A1 (en) 2007-01-18 2008-08-14 Joseph Barbosa Methods and compositions for the treatment of pain, inflammation and cancer
US8338441B2 (en) 2009-05-15 2012-12-25 Gilead Sciences, Inc. Inhibitors of human immunodeficiency virus replication
US9308236B2 (en) 2013-03-15 2016-04-12 Bristol-Myers Squibb Company Macrocyclic inhibitors of the PD-1/PD-L1 and CD80(B7-1)/PD-L1 protein/protein interactions
EA029901B1 (ru) 2013-09-04 2018-05-31 Бристол-Майерс Сквибб Компани Соединения для применения в качестве иммуномодуляторов
HRP20181251T1 (hr) 2013-09-06 2018-10-05 Aurigene Discovery Technologies Limited Derivati 1,3,4-oksadiazola i 1,3,4-tiadiazola kao imunomodulatori
CU24362B1 (es) 2013-09-06 2018-10-04 Aurigene Discovery Tech Ltd Derivados de 1,2,4-oxadiazol como inmunomoduladores
US9850225B2 (en) 2014-04-14 2017-12-26 Bristol-Myers Squibb Company Compounds useful as immunomodulators
WO2017025368A1 (fr) 2015-08-07 2017-02-16 Boehringer Ingelheim International Gmbh Acides indanylaminopyridylcyclopropanecarboxyliques, compositions pharmaceutiques et leurs utilisations
NL1041468B1 (en) 2015-09-08 2017-03-22 Bosch Gmbh Robert Metal ring component of a drive belt for a continuously variable transmisson.
WO2017042121A1 (fr) 2015-09-09 2017-03-16 Boehringer Ingelheim International Gmbh Acides [{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acétiques, compositions pharmaceutiques et utilisations associées
US10745382B2 (en) 2015-10-15 2020-08-18 Bristol-Myers Squibb Company Compounds useful as immunomodulators
US20170107216A1 (en) 2015-10-19 2017-04-20 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2016358100B2 (en) 2015-11-19 2021-05-27 Incyte Corporation Heterocyclic compounds as immunomodulators
TW201726623A (zh) 2015-12-17 2017-08-01 英塞特公司 作為免疫調節劑之雜環化合物
TWI850624B (zh) 2015-12-22 2024-08-01 美商英塞特公司 作為免疫調節劑之雜環化合物
EP3190103A1 (fr) 2016-01-08 2017-07-12 Rijksuniversiteit Groningen Inhibiteurs de l'interaction protéine/protéine pd-1/pd-l1
TWI808938B (zh) 2016-04-07 2023-07-21 美商卡默森屈有限公司 藉由投予ccr1拮抗劑與pd-1抑制劑或pd-l1抑制劑之組合減少腫瘤負荷
TW201808950A (zh) 2016-05-06 2018-03-16 英塞特公司 作為免疫調節劑之雜環化合物
WO2017202276A1 (fr) 2016-05-23 2017-11-30 中国医学科学院药物研究所 Dérivé de phénylate, procédé pour sa préparation et composition pharmaceutique et utilisations correspondantes
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
DK3472167T3 (da) 2016-06-20 2022-09-05 Incyte Corp Heterocykliske forbindelser som immunomodulatorer
WO2018005374A1 (fr) 2016-06-27 2018-01-04 Chemocentryx, Inc. Composés immunomodulateurs
AU2017294231B2 (en) 2016-07-05 2021-09-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof
JP7168551B2 (ja) 2016-07-08 2022-11-09 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な1,3-ジヒドロキシフェニル誘導体
EP3484866B1 (fr) 2016-07-14 2022-09-07 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
EP3504198B1 (fr) 2016-08-29 2023-01-25 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
US10144706B2 (en) 2016-09-01 2018-12-04 Bristol-Myers Squibb Company Compounds useful as immunomodulators
TW201823199A (zh) 2016-09-02 2018-07-01 美商北極星藥品公司 免疫檢查點抑制劑、組成物及其方法
US10771492B2 (en) 2016-09-22 2020-09-08 Microsoft Technology Licensing, Llc Enterprise graph method of threat detection
JP7106572B2 (ja) 2016-12-20 2022-07-26 ブリストル-マイヤーズ スクイブ カンパニー 免疫調節剤として有用な化合物
EP3558963B1 (fr) 2016-12-22 2022-03-23 Incyte Corporation Composés hétéroaromatiques bicycliques utilisés en tant qu'immunomodulateurs
ES2874756T3 (es) 2016-12-22 2021-11-05 Incyte Corp Derivados de triazolo[1,5-A]piridina como inmunomoduladores
IL295660A (en) 2016-12-22 2022-10-01 Incyte Corp Benzooxazole derivatives as immunomodulators
EP3558973B1 (fr) 2016-12-22 2021-09-15 Incyte Corporation Dérivés pyridine utilisés en tant qu'immunomodulateurs
ES2929193T3 (es) 2016-12-22 2022-11-25 Incyte Corp Derivados de tetrahidro imidazo[4,5-c]piridina como inductores de la internalización de PD-L1
WO2018119263A1 (fr) 2016-12-22 2018-06-28 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inducteurs de l'internalisation de pd-l1
CN108250159B (zh) 2016-12-29 2023-07-11 深圳微芯生物科技股份有限公司 脲类化合物、其制备方法及其应用
CN108395443B (zh) 2017-02-04 2021-05-04 广州丹康医药生物有限公司 抑制程序性死亡受体配体1的环状化合物及其用途
CN110461829B (zh) 2017-03-27 2023-02-28 百时美施贵宝公司 作为免疫调节剂的取代的异喹啉衍生物
JOP20180040A1 (ar) 2017-04-20 2019-01-30 Gilead Sciences Inc مثبطات pd-1/pd-l1
TW201841896A (zh) 2017-04-26 2018-12-01 大陸商南京聖和藥業股份有限公司 作為pd—l1抑制劑的雜環類化合物
CN108863963B (zh) 2017-05-08 2022-05-27 南京圣和药物研发有限公司 作为pd-l1抑制剂的杂环类化合物
CA3070794A1 (fr) * 2017-07-28 2019-01-31 Chemocentryx, Inc. Composes immunomodulateurs
JP7198269B2 (ja) 2017-08-08 2022-12-28 ケモセントリックス,インコーポレイティド 大員環免疫調節剤
US11787766B2 (en) 2017-08-18 2023-10-17 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Compound having PD-L1 inhibitory activity, preparation method therefor and use thereof
CA3075638A1 (fr) 2017-09-25 2019-03-28 Chemocentryx, Inc. Polytherapie utilisant un antagoniste du recepteur 2 de la chimiokine (ccr2) et un inhibiteur pd-1/pd-l1
WO2019070643A1 (fr) 2017-10-03 2019-04-11 Bristol-Myers Squibb Company Immunomodulateurs
CN109665968B (zh) 2017-10-16 2022-02-22 四川科伦博泰生物医药股份有限公司 并环化合物及其制备方法和用途
CN109678796B (zh) 2017-10-19 2023-01-10 上海长森药业有限公司 Pd-1/pd-l1小分子抑制剂及其制备方法和用途
CN109721527B (zh) 2017-10-27 2024-03-12 广州丹康医药生物有限公司 一种新型抗pd-l1化合物、其应用及含其的组合物
EP3707135A1 (fr) 2017-11-06 2020-09-16 Jubilant Prodel LLC Dérivés de pyrimidine utilisés en tant qu'inhibiteurs de l'activation de pd1/pd-l1
WO2019120297A1 (fr) 2017-12-22 2019-06-27 上海海雁医药科技有限公司 Immunomodulateur, son procédé de préparation et son utilisation médicale
AU2018398887B2 (en) 2017-12-29 2024-03-14 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Aromatic vinyl or aromatic ethyl derivative, preparation method therefor, intermediate, pharmaceutical composition, and application
ES2998139T3 (en) 2018-01-23 2025-02-19 Bristol Myers Squibb Co 2,8-diacyl-2,8-diazaspiro[5.5]undecane compounds useful as immunomodulators
WO2019149183A1 (fr) 2018-02-05 2019-08-08 上海和誉生物医药科技有限公司 Dérivé de biaryle, son procédé de préparation, et son application pharmaceutique
WO2019160882A1 (fr) 2018-02-13 2019-08-22 Gilead Sciences, Inc. Inhibiteurs pd -1/pd-l1
MA51232A (fr) * 2018-02-22 2020-10-07 Chemocentryx Inc Indane-amines utiles en tant qu'antagonistes de pd-l1
KR102758923B1 (ko) 2018-03-01 2025-01-24 브리스톨-마이어스 스큅 컴퍼니 면역조정제로서 유용한 화합물
WO2019174533A1 (fr) 2018-03-13 2019-09-19 广东东阳光药业有限公司 Inhibiteur de pd-1/pd-l1 à petites molécules et son utilisation dans des médicaments
EP3765453A1 (fr) 2018-03-13 2021-01-20 Jubilant Prodel LLC Composés bicycliques utilisés en tant qu'inhibiteurs de l'interaction/activation de pd1/pd-l1
RS64055B1 (sr) 2018-03-30 2023-04-28 Incyte Corp Heterociklična jedinjenja kao imunomodulatori
US20210040118A1 (en) 2018-04-03 2021-02-11 Betta Pharmaceuticals Co., Ltd Immunomodulators, compositions and methods thereof
WO2019204609A1 (fr) 2018-04-19 2019-10-24 Gilead Sciences, Inc. Inhibiteurs pd-1/pd-l1
EP4219492B1 (fr) 2018-05-11 2024-11-27 Incyte Corporation Composés hétérocycliques utilisés comme immunomodulateurs
TWI798463B (zh) 2018-07-11 2023-04-11 大陸商上海和譽生物醫藥科技有限公司 免疫抑制劑及其製備方法和在藥學上的應用
WO2020011243A1 (fr) 2018-07-12 2020-01-16 Betta Pharmaceuticals Co., Ltd Immunomodulateurs, compositions et procédés associés
BR112020026746A2 (pt) 2018-07-13 2021-03-30 Gilead Sciences, Inc. Composto, composição farmacêutica, métodos para inibir pd-1, pd-l1 e/ou a interação de pd-1/pd-l1 e para tratar câncer, e, kit para tratar ou prevenir câncer ou uma doença ou condição.
WO2020015716A1 (fr) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulateurs, compositions et procédés associés
WO2020015717A1 (fr) 2018-07-19 2020-01-23 Betta Pharmaceuticals Co., Ltd Immunomodulateurs, compositions et procédés associés
EP3831823A4 (fr) 2018-08-01 2022-04-27 Shanghai Ennovabio Pharmaceuticals Co., Ltd. Préparation et application d'un composé aromatique ayant une fonction immunorégulatrice
EP3843711A4 (fr) 2018-08-29 2022-08-03 ChemoCentryx, Inc. Méthodes de traitement du cancer avec des inhibiteurs de pd-l1 à petites molécules
CN109336857A (zh) 2018-11-13 2019-02-15 南方医科大学 一种含取代联苯的黄酮及其应用
CN109438263A (zh) 2018-11-28 2019-03-08 南方医科大学 一种含取代联苯的萘及其应用
CN109503546A (zh) 2019-01-10 2019-03-22 南方医科大学 一种间苯二酚二苯甲醚及其应用
CN109776377B (zh) 2019-02-01 2021-08-24 沈阳药科大学 吲哚啉类化合物及其制备方法和应用
CN109776445B (zh) 2019-03-28 2022-12-06 中国药科大学 苯并噁二唑类化合物及其制备方法和医药用途
CA3139526A1 (fr) 2019-05-15 2020-11-19 Chemocentryx, Inc. Composes triaryles pour le traitement de maladies pd-l1
CN110200959A (zh) 2019-05-30 2019-09-06 天津科技大学 一种黄酮类化合物的应用
CN110128415B (zh) 2019-05-31 2022-03-25 沈阳药科大学 用作免疫调节剂的吲哚啉类化合物及其制备方法
MA55325A (fr) 2019-06-20 2022-04-27 Chemocentryx Inc Composés pour le traitement de maladies pd-l1
WO2021007386A1 (fr) 2019-07-10 2021-01-14 Chemocentryx, Inc. Indanes en tant qu'inhibiteurs de pd-l1
AU2020368393B2 (en) 2019-10-16 2026-01-08 Chemocentryx, Inc. Heteroaryl-biphenyl amides for the treatment of PD-L1 diseases
BR112022006279A2 (pt) 2019-10-16 2022-06-28 Chemocentryx Inc Heteroaril-bifenil aminas para o tratamento de doenças pd-l1
CN116472045B (zh) 2020-06-23 2025-05-13 坎莫森特里克斯公司 使用杂芳基联苯基酰胺衍生物治疗癌症的方法

Also Published As

Publication number Publication date
EP3755311A4 (fr) 2021-11-10
US20190282555A1 (en) 2019-09-19
EP3755311B1 (fr) 2026-01-28
US20220175746A1 (en) 2022-06-09
US11759458B2 (en) 2023-09-19
US20200375962A1 (en) 2020-12-03
WO2019165043A3 (fr) 2020-04-30
JP7387616B2 (ja) 2023-11-28
WO2019165043A2 (fr) 2019-08-29
US10568874B2 (en) 2020-02-25
US11135210B2 (en) 2021-10-05
EP3755311A2 (fr) 2020-12-30
JP2021513996A (ja) 2021-06-03

Similar Documents

Publication Publication Date Title
MA51232A (fr) Indane-amines utiles en tant qu'antagonistes de pd-l1
MA54546A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA54547A (fr) Amides d'hétéroaryle utiles en tant qu'inhibiteurs de kif18a
MA53377A (fr) Composés de pyridin-2-one utiles en tant qu'antagonistes de smarca2
EP3883570A4 (fr) Hétérocycles fonctionnalisés utiles en tant qu'agents antiviraux
MA48994A (fr) Isoquinoléines utilisées en tant qu'inhibiteurs de hpk1
MA46745A (fr) Dérivés d'indazole en tant qu'antagonistes de l'intégrine alpha v
EP3386981A4 (fr) Hétérocycles utiles en tant qu'agents anticancereux
MA49903A (fr) Sulfonylureés et sulfonylthioureés en tant qu'inhibiteurs de nlrp3
MA41551A (fr) Hétérocycles bicycliques utilisés en tant qu'inhibiteurs de fgfr4
MA49563A (fr) Anticorps bispécifiques en tant qu'inhibiteurs de points de contrôle
MA47460A (fr) Aminotriazolopyridines utilisées en tant qu'inhibiteurs de kinase
MA46196A (fr) Composés et compositions en tant qu'inhibiteurs de récepteurs de type toll endosomal
MA45153A (fr) Dérivés de carbonucléosides substitués utiles en tant qu'agents anticancéreux
MA45244A (fr) Pyridines substituées utilisées en tant qu'inhibiteurs de dnmt1
MA45377A (fr) Composés hétérocycliques en tant qu'agents antibacteriens
EP4013496A4 (fr) Thrombosomes en tant qu'agent désactivateur d'antiagrégant plaquettaire
EP3860977A4 (fr) Antagonistes de l'intégrine
MA54567A (fr) Pyridine et composés de pyridimine en tant qu'inhibiteurs de pi3k-gamma
EP3953331A4 (fr) Pyrazolesulfonamides en tant qu'agents antitumoraux
EP3886879A4 (fr) Plaquettes en tant qu'agents de livraison
MA47736A (fr) Pyrimidopyrimidinones utiles en tant qu'inhibiteurs de la kinase wee-1
EP3481814A4 (fr) Antagonistes de l'intégrine tetrahydronaphthyridinepentanamide
MA46878A (fr) Composés de benzodiazolium en tant qu'inhibiteurs d'enac
EP3426636A4 (fr) Hétérocycles substitués en tant qu'agents de ciblage de c-myc